Welcome to our dedicated page for RAPT Therapeutics news (Ticker: RAPT), a resource for investors and traders seeking the latest updates and insights on RAPT Therapeutics stock.
RAPT Therapeutics, Inc. (NASDAQ: RAPT) is a clinical-stage biopharmaceutical company specializing in immunology-based treatments. Focused on developing and commercializing oral small molecule therapies, RAPT Therapeutics aims to address significant unmet medical needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the company creates highly selective small molecules designed to modulate critical immune drivers underlying these conditions.
RAPT Therapeutics has two main drug candidates: FLX475 (tivumecirnon) and RPT193 (zelnecirnon). FLX475 targets the C-C motif chemokine receptor 4 (CCR4) and is designed to inhibit the migration of regulatory T cells into tumors, enhancing the immune response against cancer. RPT193, also targeting CCR4, focuses on inhibiting type 2 T helper cells in inflamed tissues, offering potential relief for inflammatory diseases like atopic dermatitis and asthma.
In recent developments, RAPT Therapeutics reported promising Phase 2 data for FLX475 in combination with pembrolizumab for non-small cell lung cancer (NSCLC) patients. The company also emphasized FLX475's potential in other cancers, including head and neck cancer, gastric cancer, and non-Hodgkin lymphoma. Despite a clinical hold placed by the FDA on the Phase 2 trials for zelnecirnon due to a serious adverse event, RAPT continues to investigate and aims to resolve the issue.
Financially, RAPT Therapeutics maintains a strong cash position, reporting $158.9 million in cash and equivalents by the end of 2023. The company is diligently working to advance its clinical programs and explore additional targets in the discovery stage, ensuring a robust pipeline for future developments.
RAPT Therapeutics, Inc. (Nasdaq: RAPT), focused on immunology and oncology therapies, announced a poster presentation for FLX475, its lead oncology drug candidate, at the 2023 ASCO annual meeting scheduled for June 2-6, 2023. The poster titled "Clinical and Biological Activity of FLX475, an Oral CCR4 Antagonist, in Advanced Cancer" will be presented on June 3, 2023, from 8:00 a.m. to 11:00 a.m. ET. The abstract associated with the presentation will be released on May 25, 2023. RAPT is advancing two key drug candidates, RPT193 and FLX475, aimed at treating inflammatory diseases and cancer, respectively, showcasing their commitment to addressing significant unmet medical needs.
RAPT Therapeutics (Nasdaq: RAPT) has launched a global 14-week Phase 2a clinical trial to assess the safety and efficacy of RPT193, an oral therapy for patients with moderate-to-severe asthma. The double-blind, placebo-controlled study will involve around 100 patients with Type 2-high asthma. The trial follows promising results from a prior Phase 1b trial in atopic dermatitis. Primary endpoints include measuring the lack of asthma control, with patients transitioning to monotherapy in the final weeks. RPT193 targets the CCR4 receptor, potentially addressing significant unmet needs in asthma treatment.
RAPT Therapeutics reported its financial results for Q4 and the full year ending December 31, 2022, revealing a net loss of $23.0 million for Q4 and $83.8 million for the year. Research and development (R&D) expenses rose to $19.5 million in Q4 and $67.1 million for the year, primarily due to costs associated with lead programs RPT193 and FLX475. The company's cash position remains strong at $249.1 million, anticipated to last into mid-2025. RAPT plans to initiate a Phase 2a trial for RPT193 in asthma soon, with topline results for a related trial expected by mid-2024, delayed due to slower patient enrollment.
RAPT Therapeutics, a clinical-stage biopharmaceutical company focused on immunology, will have CEO Brian Wong participate in a fireside chat at the SVB Securities Global Biopharma Conference on February 14, 2023, at 1:40 p.m. ET. The event will discuss RAPT's efforts in developing oral small molecule therapies for inflammatory diseases and oncology, including their drug candidates RPT193 and FLX475, aimed at targeting C-C motif chemokine receptor 4 (CCR4). Investors and interested parties can access the live webcast and archived recording on RAPT's website.
RAPT Therapeutics, a clinical-stage biopharmaceutical company, announced that its CEO, Brian Wong, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 3:00 p.m. PT. The conference provides a platform for companies to discuss innovations in healthcare. RAPT focuses on developing oral small molecule therapies for inflammatory diseases and oncology. Their notable drug candidates include RPT193 and FLX475, targeting CCR4 receptors. A live webcast of the presentation will be available on their official website.
RAPT Therapeutics presented promising data at the ESMO Immuno-Oncology Congress for its ongoing Phase 1/2 trial of FLX475, showing a confirmed overall response rate of 31% in checkpoint-naïve NSCLC patients, with ongoing responses exceeding one year. Among 13 patients, 38% of those with PD-L1 positive tumors responded, while 25% responded in the PD-L1 negative group. Additionally, a separate cohort of patients with EBV+ NK/T cell lymphoma displayed four responses, including two durable complete metabolic responses. The safety profile of FLX475 remained favorable.
RAPT Therapeutics (Nasdaq: RAPT) has announced that its abstract for the ongoing Phase 1/2 study of FLX475 will be presented at the European Society for Medical Oncology Immuno-Oncology Annual Congress from December 7-9, 2022, in Geneva, Switzerland. The presentation will cover data from patients with checkpoint inhibitor-naïve NSCLC treated with FLX475 plus pembrolizumab and those with EBV-positive NK/T cell lymphoma receiving FLX475 monotherapy. The session will occur on December 8, 2022, from 12:30 to 1:15 p.m. CET.
RAPT Therapeutics announced the pricing of an underwritten public offering of 4,054,055 shares of common stock at $18.50 per share, aiming to raise approximately $75 million before expenses. The offering will close on November 22, 2022. The underwriters have an additional option to purchase up to 608,108 shares. This offering falls under a shelf registration statement declared effective on November 16, 2020. The company focuses on developing oral small molecule therapies for inflammatory diseases and oncology, with drug candidates targeting CCR4.
FAQ
What is the current stock price of RAPT Therapeutics (RAPT)?
What is the market cap of RAPT Therapeutics (RAPT)?
What does RAPT Therapeutics do?
What are the main drug candidates of RAPT Therapeutics?
What recent achievements has RAPT Therapeutics made?
What financial condition is RAPT Therapeutics in?
What is FLX475?
What is RPT193?
What is the status of the Phase 2 trials for zelnecirnon?
What recent financial results has RAPT Therapeutics reported?
How is RAPT Therapeutics funded for its ongoing operations?
What are the primary focuses of RAPT Therapeutics' research?
